Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Lifted by Deutsche Bank AG

Deutsche Bank AG lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 28.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,949 shares of the company's stock after acquiring an additional 18,939 shares during the period. Deutsche Bank AG owned approximately 0.15% of Harmony Biosciences worth $2,958,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HRMY. FMR LLC boosted its position in Harmony Biosciences by 1.9% during the 4th quarter. FMR LLC now owns 5,329,902 shares of the company's stock worth $183,402,000 after purchasing an additional 101,182 shares during the period. Vanguard Group Inc. lifted its stake in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after purchasing an additional 1,262,362 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after purchasing an additional 351,582 shares in the last quarter. Deep Track Capital LP purchased a new stake in shares of Harmony Biosciences in the fourth quarter worth about $49,894,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Harmony Biosciences by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company's stock valued at $41,739,000 after buying an additional 160,490 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Stock Performance

Harmony Biosciences stock traded down $0.38 during midday trading on Tuesday, reaching $33.79. 558,046 shares of the stock traded hands, compared to its average volume of 601,903. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 0.47 and a beta of 0.82. The firm has a fifty day moving average price of $31.55 and a two-hundred day moving average price of $34.00.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.67 EPS. On average, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HRMY shares. Needham & Company LLC reissued a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Cantor Fitzgerald raised shares of Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Mizuho raised their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.